MB-GBHC@EC2606A

Chief Scientist of Juzi Bio Purchased Shares Worth HKD 2.5 Billion

Juzi Bio repurchased 400,000 shares for approximately HKD 14.3467 million

Shaanxi Juzi Biotech Co., Ltd. Obtains Medical Device Registration Certificate for Reconstituted Collagen and Sodium Hyaluronate Composite Solution

Juzi Bio repurchased 400,000 shares

Juzi Biosciences Repurchased 400,000 Shares at HKD 34.12-34.44 per Share

Juzi Biotech Repurchased 400,000 Shares for HKD 13,581,600

Juzi Biotech Grants Nordberg Medical Global Rights to Recombinant Collagen Development

CMBI Dramatically Downgrades Jiuzi Bio's Rating and Target Price

Juzi Biosciences Repurchased 400,000 Shares for HKD 13.8144 Million

Juzi Bio Signs Strategic Cooperation Agreement with Nordberg Medical, Shifts to Core Technology-driven Growth

China Merchants Securities International Downgrades Juzi Bio to Neutral

Juzi Biotech repurchased 400,000 shares for about HKD 14.4297 million

Morgan Stanley Maintains Buy Rating for Giant Biogene

Juzi Biotech repurchased 400,000 shares for HKD 13.883 million

Morgan Stanley Downgrades Hygia Biotech's Revenue Forecast for 2025-2027

Juzi Bio repurchased 400,000 shares for about HK$13.9173 million

Juzi Biotech Focuses on New Share Repurchase Plan and Positive Broker Ratings

UBS Analyst Maintains Hold Rating on Giant Biogene

Juzi Biotech repurchased 400,000 shares for HKD 14.0364 million

UBS downgrades ZTO Bio to neutral

STARCOIN GROUP

AE LOGISTICS

GUANZE MEDICAL

WATER INDUSTRY

ZHONGSHI MINAN

IDT INT'L

HAIZHI TECH GP

MANY IDEA CLOUD

FIRST CAP GP

XL2CSOPCOIN-U

09992

09896

00700

02367

The main indices of the Hong Kong stock market experienced a significant pullback during the trading session, with the Hang Seng Index, Hang Seng Tech Index, and the China Enterprises Index all declining, showing clear structural differentiation. Leading internet and technology stocks generally faced pressure, while retail and jewelry stocks exhibited mixed performance, with individual consumer chain stocks like POP MART and MNSO standing out. Short-term capital flows were active in popular varieties, as the market focused on macro data and policy changes, with investor sentiment dominated by a wait-and-see attitude

- The Hong Kong stock market shows a general decline, with the Hang Seng Index dropping 1.24% and unable to surpass previous highs.  
- The technology sector struggles, particularly Tencent and Kuaishou, while the retail sector sees mixed results; Alibaba falls 2.82%, but Miniso rises 4.58%.  
- Macro factors such as economic data fluctuations and liquidity concerns influence investor sentiment and market dynamics.

Market Heartbeat

POP MART

MNSO

TENCENT

KUAISHOU-W

BIDU-SW

BABA-W

JD-SW

CTG DUTY-FREE

CHOW TAI FOOK

BRAINAURORA-B

MODERN LAND

GUOFUHEE

GIANT BIOGENE

MACAU E&M

FI CSOP HSI

FL2 CSOP HSI

CSOP HS TECH

FI2 CSOP HSI

Hong Kong stocks intraday | All three major indices retraced, Tencent Holdings weakened while POP MART remained active against the trend

159837

159849

516500

516930

On January 27th, GIANT BIOGENE (2367.HK) experienced weak fluctuations during the trading session, repeatedly testing the support at the 28 yuan mark without success. Throughout the day, funds continued to flow out, with a high proportion of trading occurring in the red, indicating a gradual loss of confidence among bulls, and the main positions began to loosen. The biotechnology sector has shown continued weakness over the past week due to differences in local policies. The sector's funds are extremely cautious, lacking leadership from major companies, making it difficult to ignite a bullish atmosphere in the short term. GIANT BIOGENE has not released any significant announcements recently, and the valuation support story struggles to attract new followers. The overall industry sentiment is low, with funds only able to switch between localized hotspots, leading to a further contraction in risk appetite. 

Technically, indicators such as MACD, KDJ, and RSI have all weakened, and a clear downward channel has formed on the daily chart. Although there have been occasional attempts by the main players to bottom-fish in the short term, there are no signs of an overall trend reversal, with the dominance of funds leaning more towards the bears. If there are active large orders that can reverse the trend in the intraday session, there may be a turning point; otherwise, the weak consolidation is likely to continue. 

In summary, GIANT BIOGENE is currently in a phase of dissipating bullish confidence. If the key support level of 28 yuan is breached, it may trigger a new round of technical sell-off. It is recommended that investors focus on position control, wait for unusual fund movements and intraday improvement signals, and avoid blindly betting on a rebound from the left side

Technical Forecast

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

Morning Trend | GIANT BIOGENE Bullish Confidence Wavers, Key Support at Risk?

Giant Biogene Holding Co., Ltd. (HKG:2367) saw net insider buying over the past year, with Chief Scientific Officer Daidi Fan being the largest buyer, purchasing HK$2.5 billion worth of shares. Despite a significant sale of HK$2.3 billion by Fan, it occurred above the current share price of HK$33.84. Insiders own 55% of the company, valued at approximately HK$20 billion, indicating alignment with shareholders. While no transactions occurred in the last three months, the overall insider activity suggests optimism for the company's future.

Simplywall

Giant Biogene Holding Insider Ups Holding During Year

588250

159859

Jefferies Adjusts Giant Biogene's Price Target to HK$50 From HK$55, Keeps at Buy

marketscreener

Penghua SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

Huaan Hang Seng Biotech ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Guotai CSI Bio-medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Jefferies Adjusts Giant Biogene's Price Target to HK$50 From HK$55, Keeps at Buy

Giant Biogene Holding Co. Ltd. has received approval in China for its Recombinant Type I α1 Subtype Collagen and Sodium Hyaluronate Composite Solution, the first of its kind for intradermal injection aimed at improving cheek smoothness. This product enhances the company's collagen portfolio and is expected to create new market opportunities in skin rejuvenation. The current analyst rating for Giant Biogene's stock (HK:2367) is a Hold with a price target of HK$39.50.

Tip Ranks

Giant Biogene Wins China Approval for World-First Collagen–Hyaluronate Skin Implant

Guotai Haitong analyst maintained a Buy rating on Giant Biogene Holding Co. Ltd. yesterday and set a price target of HK$43.60.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The word on The Street in general, suggests a Strong Buy analyst consensus rating for Giant Biogene Holding Co. Ltd. with a HK$52.50 average price target.

Giant Biogene Holding Co. Ltd. (2367) Receives a Buy from Guotai Haitong

06883

09633

02460

The research report from China Merchants Bank International predicts that in 2026, domestic residents' consumption will be affected by asset shrinkage and slow recovery of income expectations, leading to consumption downgrade. The report suggests focusing on companies that have made progress in globalization to hedge against domestic demand volatility risks. In terms of stock selection, it recommends paying attention to NONGFU SPRING, CR BEVERAGE, GIANT BIOGENE, and ETERNAL BEAUTY

AASTOCKS

ETERNAL BEAUTY

NONGFU SPRING

CR BEVERAGE

CITIC International expects domestic residential property values to shrink next year, with continued consumption downgrade

Morgan Stanley has maintained a Buy rating for Giant Biogene Holding Co. Ltd. with a price target of HK$42.00, while the current share price is HK$34.72. Citi also issued a Buy rating earlier, whereas UBS maintained a Hold rating. This reflects mixed analyst opinions on the company's stock performance.

Morgan Stanley Sticks to Its Buy Rating for Giant Biogene Holding Co. Ltd. (2367)

Giant Biogene Holding (SEHK:2367) is gaining attention with a new share buyback plan and positive broker ratings, despite recent negative returns. The stock is considered undervalued with a P/E ratio of 15.1x, lower than industry averages. Analysts suggest potential for price growth, but caution about China's consumer demand and skincare pricing pressures. A DCF model indicates shares are 45% below fair value, highlighting a disconnect between price and cash flow potential. Investors are encouraged to explore further opportunities using Simply Wall St's tools.

Giant Biogene Holding (SEHK:2367): Valuation Check After New Buyback Plan and Fresh Broker Buy Ratings

UBS analyst Ingrid Zhang maintained a Hold rating for Giant Biogene Holding Co. Ltd. with a price target of HK$39.50. The stock closed at HK$36.20. Despite a general Strong Buy consensus with a HK$56.45 target, another report also reiterated a Hold rating with a HK$43.00 target.

UBS Sticks to Its Hold Rating for Giant Biogene Holding Co. Ltd. (2367)

HSBC maintains a Buy rating for Giant Biogene Holding Co. Ltd. with a price target of HK$46.40, while Citi also keeps a Buy rating with a target of HK$44.60. The stock closed at HK$38.30, and analysts suggest a Strong Buy consensus with an average target of HK$61.95, indicating a 61.75% upside potential.

HSBC Sticks to Their Buy Rating for Giant Biogene Holding Co. Ltd. (2367)

HSBC Research has lowered the target price for GIANT BIOGENE to 46.4 yuan, maintaining a "Buy" rating. Due to growth pressures on the Comfy brand, profit forecasts for 2025-2027 have been reduced by 17-25%. Nevertheless, the medical aesthetics business may become a positive catalyst in 2026. Previously, GIANT BIOGENE updated its full-year performance guidance during a conference call, expecting a mid to high single-digit decline in net profit for 2025, with revenue remaining flat or slightly declining

HSBC Research lowers the target price for GIANT BIOGENE to 46.4 yuan, maintaining a "Buy" rating

$MAO GEPING(01318.HK) feels like it's not that hot, will check the excess multiple later $GIANT BIOGENE(02367.HK)

MAO GEPING

MB-GBHC@EC2606A(13629.HK)

Hong Kong stocks intraday | All three major indices retraced, Tencent Holdings weakened while POP MART remained active against the trend

Morning Trend | GIANT BIOGENE Bullish Confidence Wavers, Key Support at Risk?

Giant Biogene Holding Insider Ups Holding During Year

Jefferies Adjusts Giant Biogene's Price Target to HK$50 From HK$55, Keeps at Buy

Giant Biogene Wins China Approval for World-First Collagen–Hyaluronate Skin Implant